This was repeated in our model of medulloblastoma which demonstrated that CCR2+HSCs are responsible for the capacity of HSC transfer to enhance the efficacy of adoptive cellular therapy (Fig. 8f). This evidence concerns the gene CCR2 and medulloblastoma.